Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells

Neoplasia

Volumn 5, Issue 4, 2003, Pages 347-361

  Nightingale, Joanna ^a   Chaudhary, Khurram S ^a   Abel, Paul D ^a   Stubbs, Andrew P ^a   Romanska, Hanna M ^a   Mitchell, Stephen E ^a   Stamp, Gordon W H ^a   Lalani, El Nasir ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Androgen receptor; Apoptosis; E cadherin; Ligand; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; COMPLEMENTARY DNA; LIGAND; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL ADHESION; CELL AGGREGATION; CELL PROLIFERATION; GENE CONTROL; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 0041854246     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1476-5586(03)80028-3     Document Type: Article

References (73)

1. Wingo PA, Landis S, and Ries LA (1997). An adjustment to the 1997 estimate for new prostate cancer cases. Cancer 80, 1810-813.
2. Griffiths K (1993). Is there a best castration? Cancer 72, 3807-809.
3. Kirby RS (1996). Recent advances in the medical management of prostate cancer [see comments]. Br J Clin Pract 50, 88-93.
4. Lalani E, Laniado M, and Abel P (1997). Molecular and cellular biology of prostate cancer. Cancer Metastasis Rev 16, 29-66.
5. Lepor H, Ross A, and Walsh PC (1982). The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128, 335-40.
6. Kyprianou N, and Isaacs JT (1988). Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122, 552-62.
7. Isaacs JT, Furuya Y, and Berges R (1994). The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 5, 391-400.
8. Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, and English HF (1992). Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13, 457-64.
9. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, and Evans RM (1995). The nuclear receptor superfamily: the second decade. Cell 83, 835-39.
10. Wiener JS, Teague JL, Roth DR, Gonzales Jr ET, and Lamb DJ (1997). Molecular biology and function of the androgen receptor in genital development. J Urol 157, 1377-386.
11. Adler AJ, Danielsen M, and Robins DM (1992). Androgen-specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Natl Acad Sci USA 89, 11660-663.
12. Rennie PS, Bruchovsky N, Leco KJ, Sheppard PC, McQueen SA, Cheng H, Snoek R, Hamel A, Bock ME, MacDonald BS, Nickel BE, Chang C, Liao S, Cattini PA, and Matusik R (1993). Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol Endocrinol 7, 23-36.
13. Veldscholte J, Berrevoets CA, Ris Stalpers X, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, and Mulder E (1992). The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41, 665-69.
14. Veldscholte J, Berrevoets CA, and Mulder E (1994). Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol 49, 341-46.
15. Chaudhary KS, Abel PD, and Lalani EN (1999). Role of Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environ Health Perspect 107, 49-57.
16. Lalani E, Stubbs A, and Stamps G (1998). Molecular genetic changes in prostate cancer. Prog Pathol 4, 113-35.
17. Trapman J, and Brinkmann AO (1993). Mutations in the androgen receptor. Ann NY Acad Sci 684, 85-93.
18. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, and Shimazaki J (1993). Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46, 759-65.
19. Brinkmann AO, Jenster G, Ris Stalpers C, van der Korput JA, Bruggenwirth HT, Boehmer AL, and Trapman J (1995). Androgen receptor mutations. J Steroid Biochem Mol Biol 53, 443-48.
20. Visakorpi T, Hyytinen E, Kolvisto P, Tanner M, Keinanen R, Palmberg C, Palotle A, Tammela T, Isola J, and Kallioniemi OP (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9, 401-406 (LHM: This title is held by RPMS library ISSN 1061-4036).
21. Koivisto P, Visakorpi T, and Kallioniemi OP (1996). Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 226, 57-63.
22. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schroder FH, and van der Kwast TH (1994). Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144, 735-46.
23. Elo JP, Kvist L, Leinonen K, Isomaa V, Henttu P, Lukkarinen O, and Vihko P (1995). Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80, 3494-500.
24. Carruba G, Miceli D, D'Amico D, Farruggio R, Comito L, Montesanti A, Polito L, and Castagnetta LA (1995). Sex steroids up-regulate E-cadherin expression in hormone-responsive LNCaP human prostate cancer cells [published erratum appears in Biochem Biophys Res Commun 214 (3), 1269, 1995]. Biochem Biophys Res Commun 212, 624-31.
25. Hsieh JT, and Lin SH (1994). Androgen regulation of cell adhesion molecule gene expression in rat prostate during organ degeneration. C-CAM belongs to a class of androgen-repressed genes associated with enriched stem/amplifying cell population after prolonged castration. J Biol Chem 269, 3711-716.
26. Potter SW, Gaza G, and Morris JE (1996). Estradiol induces E-cadherin degradation in mouse uterine epithelium during the estrous cycle and early pregnancy. J Cell Physiol 169, 1-14.
27. Fujimoto J, Sakaguchi H, Hirose R, and Tamaya T (1998). Significance of sex steroids in roles of cadherin subfamily and its related proteins in the uterine endometrium and placenta. Horm Res 2, 30-36.
28. Fujimoto J, Sakaguchi H, Hirose R, and Tamaya T (1998). Sex steroidal regulation of vessel permeability associated with vessel endothelial cadherin (V-cadherin). J Steroid Biochem Mol Biol 67, 25-32.
29. Berx G, Staes K, van Hengel J, Molemans F, Bussemakers MJ, van Bokhoven A, and van Roy F (1995). Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26, 281-89.
30. Shapiro L, Fannon AM, Kwong PD, Thompson A, Lehmann MS, Grubel G, Legrand JF, Als Nielsen J, Colman DR, and Hendrickson WA (1995). Structural basis of cell-cell adhesion by cadherins [see comments]. Nature 374, 327-37.
31. Aberle H, Butz S, Stappert J, Weissig H, Kemler R, and Hoschuetzky H (1994). Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J Cell Sci 107, 3655-663.
32. Aberle H, Schwartz H, and Kemler R (1996). Cadherin-catenin complex: protein interactions and their implications for cadherin function. J Cell Biochem 61, 514-23.
33. Nathke IS, Hinck L, Swedlow JR, Papkoff J, and Nelson WJ (1994). Defining interactions and distributions of cadherin and catenin complexes in polarized epithelial cells. J Cell Biol 125, 1341-352.
34. Paul R, Ewing CM, Jarrard DF, and Isaacs WB (1997). The cadherin cell-cell adhesion pathway in prostate cancer progression. Br J Urol 1, 37-43.
35. Bussemakers MJ, van Moorselaar RJ, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FM, and Schalken JA (1992). Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52, 2916-922.
36. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, and Murphy GP (1983). LNCaP model of human prostatic carcinoma. Cancer Res 43, 1809-818.
37. Veldscholte J, Ris Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO, and Mulder E (1990). A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173, 534-40.
38. Stubbs AP, Lalani EN, Stamp GW, Hurst H, Abel P, and Waxman J (1996). Second messenger up-regulation of androgen receptor gene transcription is absent in androgen insensitive human prostatic carcinoma cell lines, PC-3 and DU-145. FEBS Lett 383, 237-40.
39. Hsu SM, Raine L, and Fanger H (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. A comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 29, 577-80.
40. Liu D, el Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W, McCrea PD, Gullick WJ, and Pignatelli M (1997). Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 77, 557-63.
41. Lalani E, Williams R, Jayaram Y, Gilbert C, Chaudhary KS, Siu L, Koumarianou A, Playford R, and Stamp GW (1999). Trefoil factor-2, human spasmolytic polypeptide, promotes branching morphogenesis in MCF-7 cells. Lab Invest 79, 537-46.
42. Kemppainen JA, Lane MV, Sar M, and Wilson EM (1992). Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. Specificity for steroids and antihormones. J Biol Chem 267, 968-74.
43. Jenster G, Trapman J, and Brinkmann AO (1993). Nuclear import of the human androgen receptor. Biochem J 293, 761-68.
44. Pinol Roma S, and Dreyfuss G (1992). Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm. Nature 355, 730-32.
45. Michael WM, Choi M, and Dreyfuss G (1995). A nuclear export signal in hnRNP Al: a signal-mediated, temperature-dependent nuclear protein export pathway. Cell 83, 415-22.
46. Lin AL, and Shain SA (1989). Androgen modulation of prostate cancer cell androgen receptor content is cell line specific. Mol Cell Endocrinol 63, 75-83.
47. Dai JL, Maiorino CA, Gkonos PJ, and Burnstein KL (1996). Androgenic up-regulation of androgen receptor cDNA expression in androgen-independent prostate cancer cells. Steroids 61, 531-39.
48. MacCalman CD, Farookhi R, and Blaschuk OW (1994). Estradiol regulates E-cadherin mRNA levels in the surface epithelium of the mouse ovary. Clin Exp Metastasis 12, 276-82.
49. Blaschuk OW, and Farookhi R (1989). Estradiol stimulates cadherin expression in rat granulosa cells. Dev Biol 136, 564-67.
50. Fujimoto J, Ichigo S, Hori M, and Tamaya T (1996). Alteration of Ecadherin, alpha- and beta-catenin mRNA expression in human uterine endometrium during the menstrual cycle. Gynecol Endocrinol 10, 187-91.
51. Fujimoto J, Ichigo S, Hori M, Morishita S, and Tamaya T (1996). Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and alpha- and beta-catenin mRNA expressions, J Steroid Biochem Mol Biol 57, 275-82.
52. Bonaccorsi L, Carloni V, Muratori M, Salvadori A, Giannini A, Carini M, Serio M, Forti G, and Baldi E (2000). Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology 141, 3172-182.
53. Hennig G, Behrens J, Truss M, Frisch S, Reichmann E, and Birchmeler W (1995). Progression of carcinoma cells is associated with alterations in chromatin structure and factor binding at the E-cadherin promoter in vivo. Oncogene 11, 475-84.
54. Bussemakers MJ, Giroldi LA, van Bokhoven A, and Schalken JA (1994). Transcriptional regulation of the human E-cadherin gene in human prostate cancer cell lines: characterization of the human E-cadherin gene promoter. Biochem Biophys Res Commun 203, 1284-290.
55. Aberle H, Bauer A, Stappert J, Kispert A, and Kemler R (1997). Beta-acatenin is a target for the ubiquitin-proteasome pathway. EMBO J 16, 3797-804.
56. Hinck L, Nathke IS, Papkoff J, and Nelson WJ (1994). Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 125, 1327-340.
57. Fagotto F, Gluck U, and Gumbiner BM (1998). Nuclear localization signal-independent and importin/karyopherin-independent nuclear import of beta-catenin. Curr Biol 8, 181-90.
58. Korinek V, Barker N, Willert K, Molenaar M, Roose J, Wagenaar G, Markman M, Lamers W, Destree O, and Clevers H (1998). Two members of the Tcf family implicated in Wnt/beta-catenin signaling during embryogenesis in the mouse. Mol Cell Biol 18, 1248-256.
59. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, and Kinzler KW (1998). Identification of c-MYC as a target of the APC pathway [see comments]. Science 281, 1509-512.
60. Yamamoto M, Bharti A, Li Y, and Kufe D (1997). Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 272, 12492-494.
61. Chitaev NA, Averbakh AZ, Troyanovsky RB, and Troyanovsky SM (1998). Molecular organization of the desmoglein-plakoglobin complex. J Cell Sci 111, 1941-949.
62. Westin P, Stattin P, Damber JE, and Bergh A (1995). Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol 146, 1368-375.
63. Kyprianou N, English HF, and Isaacs JT (1990). Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50, 3748-753.
64. Geck P, Szelei J, Jimenez J, Lin TM, Sonnenschein C, and Soto AM (1997). Expression of novel genes linked to the androgen-induced, proliferative shutoff in prostate cancer cells. J Steroid Biochem Mol Biol 63, 211-18.
65. Joly Pharaboz MO, Soave MC, Nicolas B, Mebarki F, Renaud M, Foury O, Morel Y, and Andre JG (1995). Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J Steroid Biochem Mol Biol 55, 67-76.
66. Marcelli M, Haidacher SJ, Plymate SR, and Birnbaum RS (1995). Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid [published erratum appears in Endocrinology 136 (5), 2319, 1995]. Endocrinology 136, 1040-1048.
67. Heisler LE, Evangelou A, Lew AM, Trachtenberg J, Elsholtz HP, and Brown TJ (1997). Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol Cell Endocrinol 126, 59-73.
68. Lu S, Tsai SY, and Tsai MJ (1997). Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res 57, 4511-516.
69. Kokontis JM, Hay N, and Liao S (1998). Progression of LNCaP Prostate tumour cells during androgen deprivation: hormone independent growth repression of proliferation by androgen, and role for p27Kio1 in androgen-induced cell cycle arrest. Mol Endocrinol 7, 941-53.
70. Lapointe J, and Labrie C (2001). Role of cyclin-dependent kinase inhibitor p27kip1 in androgen-induced inhibition of CAMA-1 breast cancer cell poliferation. Endocrinology 142, 4331-338.
71. Geck P, Maffini MV, Szelei J, Sonnenschein C, and Soto AM (2000). Androgen-induced proliferative quiescence in prostate cancer cells: the role of AS3 as its mediator. Proc Natl Acad Sci USA 97, 10185-190.
72. Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C, and Day KC (1999). E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem 274, 9656-664,
73. Kantak SS, and Kramer RH (1998). E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Bio1 Chem 273, 16953-961